1. Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation. 2012 Jan 17;125(2):324–34.
2. Sanchez Luna M, Franco ML, Bernardo B. Therapeutic strategies in pulmonary hypertension of the newborn: where are we now?. Curr Med Chem. 2012 Oct 1;19(27):4640–53.
3. Sebkhi A, Strange JW, Phillips SC, Wharton J, Wilkins MR. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation. 2003 Jul 1;107(25):3230–5.
4. Wharton J, Strange JW, Møller GM, Growcott EJ, Ren X, Franklyn AP, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med. 2005 Jul 1;172(1):105–13.
5. Enomoto M, Jain A, Pan J, Shifrin Y, Van Vliet T, McNamara PJ, et al. Newborn rat response to single vs. combined cGMP-dependent pulmonary vasodilators. Am J Physiol Lung Cell Mol Physiol. 2014 Jan;306(2):L207–15.